Screening for adrenal suppression in children with inflammatory bowel disease discontinuing glucocorticoid therapy

Table 1 The clinical characteristics of the 59 paediatric patients with inflammatory bowel disease (IBD)

Diagnosis CD/IBDU/UC*	22/11/26
Male/female	29/30
Age at the time of the study (median, range)	14 yrs (2.6–18)
Prednisolone daily dose
10 mg	21
5 mg	18
5 mg on alternate days	20
Length of the prednisolone therapy (months; median, range)	5 (0.5–39)
Maintenance medication**
5-ASA	27
5-ASA and/or Aza	19
TNF-α-antagonist	11
No medication	2

The first morning cortisol level was analyzed during weaning or at the end of oral prednisolone therapy. *CD: Crohn’s disease; IBDU: unclassified colitis; UC: ulcerative colitis. **5-ASA: 5-acetosalicylic acid; Aza: azathioprine.

ISSN: 1471-230X